Review: Nonergot dopamine agonists reduce symptoms in the restless legs syndrome but may be discontinued due to adverse events

摘要

Are nonergot dopamine agonists (NEDAs) effective and safe for the restless legs syndrome (RLS)?nnReview scopennArticles selected compared NEDAs with placebo in patients with RLS. Outcomes were treatment response (score of 1 or 2, very much or much improved, on the 7-point Clinical Global Impression-Improvement scale), adjusted mean change from baseline in the International RLS Study Group Scale score, treatment discontinuation due to adverse events, and adverse events. nnReview methodsnnMEDLINE, EMBASE/Excerpta Medica, CINAHL, and Web of Science (to Jul 2007); Web sites of US Food and Drug Administration, European Agency for the Evaluation of Medicinal Products, and manufacturers of NEDAs (Aug 2007); and reference lists were searched for English-language randomized controlled trials (RCTs). 14 trials (n = 3197, mean age 51 to 76 y, duration of follow-up 1 to 12 wk) met the selection criteria. Study quality was high (median Jadad score 4 out of 5).